Sachin Malde1, Roland Umbach2, Jessica R Wheeler3, Lyubov Lytvyn4, Jean-Nicholas Cornu5, Mauro Gacci6, Christian Gratzke7, Thomas R W Herrmann8, Charalampos Mamoulakis9, Malte Rieken10, Mark J Speakman11, Stavros Gravas12, Marcus J Drake13, Gordon H Guyatt14, Kari A O Tikkinen15. 1. Department of Urology, Guy's and St Thomas' NHS Foundation Trust, London, UK. 2. Department of Urology, Klinikum Sindelfingen-Bӧblingen, Sindelfingen, Germany. 3. Bristol Randomised Trials Collaboration, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Bristol Urological Institute, North Bristol NHS Trust, Southmead Hospital, Bristol, UK. 4. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada. 5. Department of Urology, Charles-Nicolle University Hospital, Rouen Cedex, France. 6. Department of Minimally Invasive and Robotic Urologic Surgery and Kidney Transplantation, University of Florence, Florence, Italy. 7. Department of Urology, University Hospital Freiburg, Freiburg, Germany. 8. Department of Urology, Kantonsspital Frauenfeld, Frauenfeld, Switzerland. 9. Department of Urology, University General Hospital of Heraklion, University of Crete Medical School, Heraklion, Crete, Greece. 10. University of Basel, Basel, Switzerland. 11. Department of Urology, Taunton & Somerset Hospital, Taunton, UK. 12. Department of Urology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece. 13. Bristol Urological Institute, North Bristol NHS Trust, Southmead Hospital, Bristol, UK; Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK. 14. Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada. 15. Department of Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; Department of Surgery, South Karelia Central Hospital, Lappeenranta, Finland. Electronic address: kari.tikkinen@helsinki.fi.
Abstract
CONTEXT: Understanding men's values and preferences in the context of personal, physical, emotional, relational, and social factors is important in optimising patient counselling, facilitating treatment decision-making, and improving guideline recommendations. OBJECTIVE: To systematically review the available evidence regarding the values, preferences, and expectations of men towards the investigation and treatment (conservative, pharmacological, and surgical) of male lower urinary tract symptoms (LUTS). EVIDENCE ACQUISITION: We searched electronic databases until August 31, 2020 for quantitative and qualitative studies that reported values and preferences regarding the investigation and treatment of LUTS in men. We assessed the quality of evidence and risk of bias using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) and GRADE Confidence in the Evidence from Reviews of Qualitative Research (CERQual) approaches. EVIDENCE SYNTHESIS: We included 25 quantitative studies, three qualitative studies, and one mixed-methods study recruiting 9235 patients. Most men reported urodynamic testing to be acceptable, despite discomfort or embarrassment, as it significantly informs treatment decisions (low certainty evidence). Men preferred conservative and less risky treatment options, but the preference varied depending on baseline symptom severity and the risk/benefit characteristics of the treatment (moderate certainty). Men preferred pharmacological treatments with a low risk of erectile dysfunction and those especially improving urgency incontinence (moderate certainty). Other important preference considerations included reducing the risk of acute urinary retention or surgery (moderate certainty). CONCLUSIONS: Men prefer lower-risk management options that have fewer sexual side effects and are primarily effective at improving urgency incontinence and nocturia. Overall, the evidence was rated to be of low to moderate certainty. This review can facilitate the treatment decision-making process and improve the trustworthiness of guideline recommendations. PATIENT SUMMARY: We thoroughly reviewed the evidence addressing men's values and preferences regarding the management of urinary symptoms and found that minimising adverse effects is particularly important. Further research to understand other factors that matter to men is required.
CONTEXT: Understanding men's values and preferences in the context of personal, physical, emotional, relational, and social factors is important in optimising patient counselling, facilitating treatment decision-making, and improving guideline recommendations. OBJECTIVE: To systematically review the available evidence regarding the values, preferences, and expectations of men towards the investigation and treatment (conservative, pharmacological, and surgical) of male lower urinary tract symptoms (LUTS). EVIDENCE ACQUISITION: We searched electronic databases until August 31, 2020 for quantitative and qualitative studies that reported values and preferences regarding the investigation and treatment of LUTS in men. We assessed the quality of evidence and risk of bias using the Grading of Recommendation, Assessment, Development and Evaluation (GRADE) and GRADE Confidence in the Evidence from Reviews of Qualitative Research (CERQual) approaches. EVIDENCE SYNTHESIS: We included 25 quantitative studies, three qualitative studies, and one mixed-methods study recruiting 9235 patients. Most men reported urodynamic testing to be acceptable, despite discomfort or embarrassment, as it significantly informs treatment decisions (low certainty evidence). Men preferred conservative and less risky treatment options, but the preference varied depending on baseline symptom severity and the risk/benefit characteristics of the treatment (moderate certainty). Men preferred pharmacological treatments with a low risk of erectile dysfunction and those especially improving urgency incontinence (moderate certainty). Other important preference considerations included reducing the risk of acute urinary retention or surgery (moderate certainty). CONCLUSIONS: Men prefer lower-risk management options that have fewer sexual side effects and are primarily effective at improving urgency incontinence and nocturia. Overall, the evidence was rated to be of low to moderate certainty. This review can facilitate the treatment decision-making process and improve the trustworthiness of guideline recommendations. PATIENT SUMMARY: We thoroughly reviewed the evidence addressing men's values and preferences regarding the management of urinary symptoms and found that minimising adverse effects is particularly important. Further research to understand other factors that matter to men is required.
Authors: Antonio Alcaraz; Mauro Gacci; Vincenzo Ficarra; José Medina-Polo; Andrea Salonia; Jesús M Fernández-Gómez; Alexandru Ciudin; David Castro-Díaz; Alfredo Rodríguez-Antolín; Joaquín Carballido-Rodríguez; José M Cózar-Olmo; Santiago Búcar-Terrades; Noemí Pérez-León; Francisco J Brenes-Bermúdez; José M Molero-García; Antonio Fernández-Pro Ledesma; Michael Herdman; José Manasanch; Javier C Angulo; On Behalf Of The Qualiprost Study Group Journal: J Clin Med Date: 2022-02-12 Impact factor: 4.241
Authors: Martin J Connor; Mesfin G Genie; David Burns; Edward J Bass; Michael Gonzalez; Naveed Sarwar; Alison Falconer; Stephen Mangar; Tim Dudderidge; Vincent Khoo; Mathias Winkler; Hashim U Ahmed; Verity Watson Journal: Eur Urol Open Sci Date: 2021-12-20
Authors: Tom Vredeveld; Esther van Benten; Rikie E P M Beekmans; M Patrick Koops; Johannes C F Ket; Jurgen Mollema; Stephan P J Ramaekers; Jan J M Pool; Michel W Coppieters; Annelies L Pool-Goudzwaard Journal: BMJ Open Date: 2022-04-29 Impact factor: 3.006
Authors: Antonio Alcaraz; David Castro-Díaz; Mauro Gacci; Andrea Salonia; Vincenzo Ficarra; Joaquín Carballido-Rodríguez; Alfredo Rodríguez-Antolín; José Medina-Polo; Jesús M Fernández-Gómez; José M Cózar-Olmo; Santiago Búcar-Terrades; Noemí Pérez-León; Francisco J Brenes-Bermúdez; José M Molero-García; Antonio Fernández-Pro-Ledesma; Michael Herdman; Javier C Angulo; José Manasanch Journal: J Clin Med Date: 2022-06-22 Impact factor: 4.964
Authors: Stacey A Kenfield; Scott R Bauer; Elizabeth Y Wang; Benjamin N Breyer; Austin W Lee; Natalie Rios; Akinyemi Oni-Orisan; Michael A Steinman; Ida Sim Journal: JMIR Hum Factors Date: 2021-12-24